154 related articles for article (PubMed ID: 37493903)
1. Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study.
Chasan O; Mirioglu S; Artan AS; Gursu M; Kazancioglu R; Elcioglu OC
Clin Exp Nephrol; 2023 Nov; 27(11):912-918. PubMed ID: 37493903
[TBL] [Abstract][Full Text] [Related]
2. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease.
Grampsas SA; Chandhoke PS; Fan J; Glass MA; Townsend R; Johnson AM; Gabow P
Am J Kidney Dis; 2000 Jul; 36(1):53-7. PubMed ID: 10873872
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients.
Nishiura JL; Neves RF; Eloi SR; Cintra SM; Ajzen SA; Heilberg IP
Clin J Am Soc Nephrol; 2009 Apr; 4(4):838-44. PubMed ID: 19339428
[TBL] [Abstract][Full Text] [Related]
4. Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.
Bargagli M; Dhayat NA; Anderegg M; Semmo M; Huynh-Do U; Vogt B; Ferraro PM; Fuster DG
Clin J Am Soc Nephrol; 2020 Jul; 15(7):1007-1014. PubMed ID: 32527945
[TBL] [Abstract][Full Text] [Related]
5. Renal stone disease in autosomal dominant polycystic kidney disease.
Torres VE; Wilson DM; Hattery RR; Segura JW
Am J Kidney Dis; 1993 Oct; 22(4):513-9. PubMed ID: 8213789
[TBL] [Abstract][Full Text] [Related]
6. Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease.
Ferraz RR; Fonseca JM; Germino GG; Onuchic LF; Heilberg IP
Urolithiasis; 2014 Aug; 42(4):301-7. PubMed ID: 24817661
[TBL] [Abstract][Full Text] [Related]
7. [The change of human Na+/dicarboxylate co-transporter 1 expression in the kidney and its relationship with pathogenesis of nephrolithiasis].
He Y; Chen X; Yu Z
Zhonghua Yi Xue Za Zhi; 2001 Sep; 81(17):1066-9. PubMed ID: 11758258
[TBL] [Abstract][Full Text] [Related]
8. Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease.
Cho Y; Sautenet B; Rangan G; Craig JC; Ong ACM; Chapman A; Ahn C; Chen D; Coolican H; Kao JT; Gansevoort R; Perrone R; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Gutman T; Howell M; Ju A; Manera KE; Teixeira-Pinto A; Hamiwka LA; Tong A
Trials; 2017 Nov; 18(1):560. PubMed ID: 29169385
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
[TBL] [Abstract][Full Text] [Related]
10. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
11. Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity in TAME-PKD Clinical Trial Participants.
Hallows KR; Althouse AD; Li H; Saitta B; Abebe KZ; Bae KT; Miskulin DC; Perrone RD; Seliger SL; Watnick TJ
Kidney360; 2021 May; 2(5):795-808. PubMed ID: 34316721
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of sirtuin 1 (SIRT1) levels in autosomal dominant polycystic kidney disease.
Ozkan Kurtgoz P; Karakose S; Cetinkaya CD; Erkus E; Guney I
Int Urol Nephrol; 2022 Jan; 54(1):131-135. PubMed ID: 33864594
[TBL] [Abstract][Full Text] [Related]
13. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.
Brosnahan GM; You Z; Wang W; Gitomer BY; Chonchol M
Curr Hypertens Rev; 2021; 17(3):228-237. PubMed ID: 32807060
[TBL] [Abstract][Full Text] [Related]
14. Urinary Citrate Is Associated with Kidney Outcomes in Early Polycystic Kidney Disease.
Rocha DR; Xue L; Gomes Sousa HM; Carvalho Matos AC; Hoorn EJ; Salih M; Heilberg IP
Kidney360; 2022 Dec; 3(12):2110-2115. PubMed ID: 36591350
[TBL] [Abstract][Full Text] [Related]
15. More dissimilarities than affinities between DNAJB11-PKD and ADPKD.
Pisani I; Allinovi M; Palazzo V; Zanelli P; Gentile M; Farina MT; Giuliotti S; Cravedi P; Delsante M; Maggiore U; Fiaccadori E; Manenti L
Clin Kidney J; 2022 Jun; 15(6):1179-1187. PubMed ID: 35664268
[TBL] [Abstract][Full Text] [Related]
16. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
[TBL] [Abstract][Full Text] [Related]
17. Increased activity of the renal kallikrein-kinin system in autosomal dominant polycystic kidney disease in rats, but not in humans.
Braun C; Kleemann T; Birck R; Hilgenfeldt U; Riester U; Tschöpe C; van der Woude FJ; Rohmeiss P
Int Immunopharmacol; 2002 Dec; 2(13-14):1949-56. PubMed ID: 12489808
[TBL] [Abstract][Full Text] [Related]
18. Hospital-based inpatient resource utilization associated with autosomal dominant polycystic kidney disease in the US.
Blanchette CM; Craver C; Belk KW; Lubeck DP; Rossetti S; Gutierrez B
J Med Econ; 2015 Apr; 18(4):303-11. PubMed ID: 25372357
[TBL] [Abstract][Full Text] [Related]
19. The association of nephrolithiasis and autosomal dominant polycystic kidney disease.
Torres VE; Erickson SB; Smith LH; Wilson DM; Hattery RR; Segura JW
Am J Kidney Dis; 1988 Apr; 11(4):318-25. PubMed ID: 3354568
[TBL] [Abstract][Full Text] [Related]
20. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
